bendamustine hydrochloride - Profile

What are the generic drug sources for bendamustine hydrochloride and what is the scope of patent protection?

Bendamustine hydrochloride is the generic ingredient in five branded drugs marketed by Accord Hlthcare, Apotex, Breckenridge, Dr Reddys, Eugia Pharma, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Cephalon, Eagle Pharms, Baxter Hlthcare Corp, Hospira, and Azurity, and is included in sixteen NDAs. There are thirty-three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bendamustine hydrochloride has one hundred and fifty-seven patent family members in thirty-two countries.

There are six tentative approvals for this compound.

Summary for bendamustine hydrochloride

International Patents:	157
US Patents:	33
Tradenames:	5
Applicants:	13
NDAs:	16
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bendamustine hydrochloride

Generic filers with tentative approvals for BENDAMUSTINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		100MG/VIAL	POWDER;IV (INFUSION)
		25MG/VIAL	POWDER;IV (INFUSION)
		100MG/VIAL	POWDER;IV (INFUSION)

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for BENDAMUSTINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELRAPZO	Injection	bendamustine hydrochloride	100 mg/4 mL (25 mg/mL) multiple-dose vials	205580	1	2018-07-17
BENDEKA	Injection	bendamustine hydrochloride	100 mg/4 mL (25 mg/mL) multiple-dose vials	208194	1	2017-05-04
TREANDA	Injection	bendamustine hydrochloride	90 mg/mL, 0.5 mL and 2 mL in single- dose vials	022249	1	2014-06-19
TREANDA	Injection	bendamustine hydrochloride	25 mg/vial and 100 mg/vial	022249	10	2013-06-04

US Patents and Regulatory Information for bendamustine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205574-001	Dec 7, 2022	AP	RX	No	No
Accord Hlthcare	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205574-002	Dec 7, 2022	AP	RX	No	No
Apotex	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	204230-001	Jun 5, 2023		DISCN	No	No
Apotex	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	204230-002	Jun 5, 2023		DISCN	No	No
Breckenridge	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205447-001	Feb 14, 2023		DISCN	No	No
Breckenridge	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205447-002	Feb 14, 2023		DISCN	No	No
Dr Reddys	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205376-001	Dec 7, 2022	AP	RX	No	No

Expired US Patents for bendamustine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eagle Pharms	BELRAPZO	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	205580-001	May 15, 2018

International Patents for bendamustine hydrochloride

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4218756	PROCÉDÉ DE TRAITEMENT DE CONDITIONS SENSIBLES À LA BENDAMUSTINE CHEZ DES PATIENTS NÉCESSITANT DES VOLUMES RÉDUITS POUR ADMINISTRATION (METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION)
Japan	6381761
Spain	2875374
Serbia	65177	FORMULACIJE BENDAMUSTINA (FORMULATIONS OF BENDAMUSTINE)
European Patent Office	1863452	COMPOSITIONS PHARMACEUTIQUES DE BENDAMUSTINE POUR LYPOPHILISER (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)
Denmark	3533447
Poland	3533447

Investment Scenario and Fundamentals Analysis for Bendamustine Hydrochloride

Last updated: February 19, 2026

What is the current market status of bendamustine hydrochloride?

Bendamustine hydrochloride is an alkylating agent used for treating non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is marketed under brand names such as Treanda (Cephalon/Teva) and Bosulif (Pfizer). Its global sales in 2022 reached approximately $620 million, with projections to grow at a compound annual growth rate (CAGR) of around 4% through 2027, driven by expanding indications and growing prevalence of hematologic malignancies.

What are the key drivers and risks impacting bendamustine hydrochloride's investment outlook?

Drivers:

• Growing Hematologic Cancers: The global incidence of NHL and CLL is increasing, fueling demand for bendamustine-based regimens. The WHO reported around 544,000 new NHL cases globally in 2020.
• Regulatory Approvals: Several markets including the U.S. and Europe have approved bendamustine for first-line and relapsed settings. Expanding approved indications, especially in combination therapies, could boost sales.
• Patient Demographics: Aging populations in North America and Europe are associated with higher cancer prevalence, increasing the market size.
• Pipeline Developments: Ongoing clinical trials aim to expand its use into multiple myeloma and other lymphoid malignancies, which could open new revenue streams.

Risks:

• Generic Competition: Patent expirations have led to generic versions for some formulations, exerting price pressure.
• Regulatory Risks: Future approval delays or restrictions on indications could reduce market potential.
• Market Saturation: Competition from other chemotherapy agents and targeted therapies such as CAR-T cells and BTK inhibitors (e.g., Ibrutinib) poses threats.
• Safety Profile Concerns: Risks of myelosuppression and secondary malignancies may limit use or limit approval in certain markets.

What are the fundamental financials and R&D considerations?

Revenue and Market Share

• Leading branded products like Treanda generated $610 million globally in 2022.
• Market share in NHL and CLL segments remains robust but declining due to generics in some regions.

Cost Structure

• Manufacturing involves complex synthesis with high regulatory standards.
• R&D costs for clinical trials are estimated at $50-$150 million per program, focusing on combination regimens, new indications, and novel formulations such as liposomal delivery systems.

Patent Landscape

• Primary patents in the U.S. extend into 2024, with orphan drug exclusivity until 2026 for specific indications.
• Several jurisdictions have a 20-year patent protection period from filing, but patent challenges and litigation are ongoing.

Competitive Landscape

Company	Key Products	Market Share	Note
Teva, Cephalon	Treanda	~35%	Leading branded formulation
Pfizer	Bosulif (other indications)	Limited	Focus on CML, not NHL/CLL
Mergers and Acquisitions	Numerous, including trading of assets	N/A	M&A activity impacts market dynamics

R&D Pipeline and New Indications

• Several clinical trials are underway for bendamustine combinations in multiple myeloma, AML, and solid tumors.
• Development of targeted delivery mechanisms like liposomal formulations aims to enhance efficacy and reduce toxicity.

What are the investment implications?

• The market remains attractive for entities with drug assets in late-stage development or with patent exclusivity extending into the mid-2020s.
• Patent expiry timelines necessitate diversification strategies, including pipeline expansion or synergy with targeted therapies.
• Licensing or partnership deals remain prevalent, especially for combination regimens or new delivery technologies.
• The growth prospects are tempered by generic competition and market saturation; thus, long-term value creation depends on innovation and expanding indications.

Key financial metrics (estimates and projections)

Metric	2022	2023	2024	Notes
Global Revenue	$620M	$650M	$680M	Growth driven by new approvals
R&D Investment	$50M-$150M	Similar	Similar	Focus on combination therapy clinical trials
Patent Expiry	2024	2024	N/A	Patent cliff approaches in key markets

---

Key Takeaways

• Bendamustine hydrochloride is established in NHL and CLL treatment with a >$600M global market.
• Growth is driven by expanding indications, new combinations, and pipeline advancements.
• Competitive threats include patent expiries, generics, and novel therapies such as CAR-T cells.
• Significant R&D investment focused on new indications, formulations, and combination regimens.
• Investment decisions hinge on pipeline success, patent protection, and market dynamics.

---

FAQs

1. How soon will patent expiry impact bendamustine's sales?
Patent protection in major markets expires by 2024, which is likely to cause generic entry and price erosion starting that year.

2. Are there generic alternatives currently available?
Yes, several generic versions are available, especially in regions where patent protections have expired or are soon to expire.

3. What new indications are under clinical investigation?
Trials are exploring bendamustine in multiple myeloma, AML, and as part of combination regimens for solid tumors, which may extend its lifecycle.

4. How does bendamustine compare to targeted therapies?
Although traditionally used chemotherapy, its role is challenged by targeted agents like BTK inhibitors and CD20 monoclonals which can offer improved safety and efficacy profiles.

5. What R&D activities could influence future revenue?
Development of liposomal formulations, new combinations, or expanded indications can provide growth opportunities and delay commoditization.

---

References

1. World Health Organization. (2021). Cancer fact sheet.
2. GlobalData. (2022). Bendamustine hydrochloride market analysis.
3. U.S. Food and Drug Administration. (2022). Drug patents and exclusivity data.
4. EvaluatePharma. (2022). Oncology drug market forecasts.
5. ClinicalTrials.gov. (2023). Clinical trials involving bendamustine.

[1] World Health Organization. (2021). Cancer fact sheet.
[2] GlobalData. (2022). Bendamustine hydrochloride market analysis.
[3] U.S. Food and Drug Administration. (2022). Drug patents and exclusivity data.
[4] EvaluatePharma. (2022). Oncology drug market forecasts.
[5] ClinicalTrials.gov. (2023). Clinical trials involving bendamustine.